Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TORL-1-23 |
Synonyms | |
Therapy Description |
TORL-1-23 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN6 linked to monomethyl auristatin E (MMAE), which potentially inhibits growth of CLDN6-expressing tumors (PMID: 36884217). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TORL-1-23 | TORL 1-23|TORL1-23|CLDN6-23-ADC|TORL123 | CLDN6 Antibody 8 | TORL-1-23 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN6 linked to monomethyl auristatin E (MMAE), which potentially inhibits growth of CLDN6-expressing tumors (PMID: 36884217). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05103683 | Phase I | TORL-1-23 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | Recruiting | USA | 0 |